While GLP1‐receptor agonists, SGLT2‐inhibitors and TZD‐derivatives may be most effective in this respect, the use of the latter may be hampered by potential cardiovascular safety profile issues, namely heart failure. The gene discussed is GLP1R; the disease is heart failure.